Time reports that some experts have raised concerns about 23andMe's new direct-to-consumer pharmacogenetic tests.
The companies have launched a center that offers consulting and management specifically for genomically targeted or precision medicine trials.
The companies are creating a new center that will offer support services to biopharmaceutical companies, CROs, and others in designing genetically informed clinical trials.
The company will now offer free genetic testing to patients at risk for acute hepatic porphyrias, a class of diseases for which it is developing a treatment.
The companies are working together to help insurers reduce wasteful spending and spur use of medically necessary tests.
Cigna worked with InformedDNA to come up with scenarios under which it would cover whole-exome sequencing, although it still considers whole-genome analysis investigational.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.